6489 LOGO20THELANSIS 12

Based on the Thelansis market insight report on anorexia-cachexia Syndrome which provides a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.

Anorexia-Cachexia-Syndrome-CS-forecast

https://thelansis.com/reports/anorexia-cachexia-syndrome-cs-market-insight-report/

The overall prevalence of Cachexia is ranging 0.19% to 0.23% in the USA and in the EU the overall prevalence ranges from 0.28% to 0.32%.

Comprehensive insight on patient segmentation based on age, sex, Critical Illness (AIDS, Cancer, COPD, Kidney Failure, Rheumatoid Arthritis, Chronic Heart Failure, Diabetes, and Other), Severity (mild, Moderate & Severe), Other Potential Mediators (Testosterone, Insulin-like growth factor I, Myostatin, Adrenal hormones ), Signs & Symptoms (Anorexia, Inflammation, Insulin resistance, Hypogonadism, Anemia and Others) , Clinical Manifestations, Treatment types (supportive therapy) has been provided into the epidemiology section of the Cachexia Syndrome (CS) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.

KOL database for PMR

In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Helsinn Therapeutics, Pfizer, AVEO Pharmaceuticals, Inc., Active/ Faraday Pharmaceuticals, NGM Biopharmaceuticals, Inc, GlaxoSmithKline, GTx, NGM Biopharmaceuticals, Inc, Biogen, Janssen Research & Development, LLC, Celgene, Pinta Biotherapeutics, who are targeting the Cachexia Syndrome (CS) market. Looking at the current clinical development and assets progress card, it would really be a great opportunity for the pharmaceutical company to build products around the treatment of Cachexia Syndrome (CS) specifically for moderate to severe patients.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Other Reports:-

Myasthenia gravis (MG) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Tourette syndrome (TS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Eosinophilic esophagitis (EoE) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report  – 2020 To 2030

Crohn’s disease – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Myasthenia gravis (MG), Tourette syndrome (TS, Eosinophilic esophagitis (EoE), Cachexia Syndrome (CS), Helsinn Therapeutics, AVEO Pharmaceuticals, Crohn’s Disease, GlaxoSmithKline